Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.65 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.65 |
| ▸ | HTT | P42858 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.58 |
| ▸ | GRM5 | P41594 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.53 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.53 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.53 |
| ▸ | KDM1A | O60341 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.52 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23387883 | 0.92 | ALDH1A1 (0.59) | ALDH1A1L3MBTL1HTTMAPTSMN1; SMN2 | |
| SCHEMBL29634591 | 0.92 | ALDH1A1 (0.59) | ALDH1A1L3MBTL1HTTMAPTSMN1; SMN2 | |
| SCHEMBL1116630 | 0.89 | ALDH1A1 (0.78) | ALDH1A1L3MBTL1HTTMAPTSMN1; SMN2 | |
| SCHEMBL3427705 | 0.86 | ALDH1A1 (0.74) | ALDH1A1L3MBTL1HTTMAPTSMN1; SMN2 | |
| SCHEMBL3427969 | 0.86 | ALDH1A1 (0.70) | ALDH1A1L3MBTL1HTTMAPTSMN1; SMN2 | |
| SCHEMBL29722613 | 0.85 | ALDH1A1 (0.60) | ALDH1A1L3MBTL1HTTMAPTSMN1; SMN2 | |
| SCHEMBL10143960 | 0.85 | ALDH1A1 (0.77) | ALDH1A1L3MBTL1HTTMAPTSMN1; SMN2 | |
| SCHEMBL1116654 | 0.85 | ALDH1A1 (0.60) | ALDH1A1L3MBTL1HTTMAPTSMN1; SMN2 | |
| SCHEMBL4414127 | 0.85 | ALDH1A1 (0.77) | ALDH1A1L3MBTL1HTTMAPTSMN1; SMN2 | |
| SCHEMBL5777586 | 0.85 | ALDH1A1 (0.58) | ALDH1A1L3MBTL1HTTMAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117285525-A | Novel isoxazolyl ether derivatives as GABAA alpha 5PAM | 豪夫迈·罗氏有限公司 | 2023-12-26 | — | — | CN | claimed |
| CN-109923113-B | Isoxazolyl ether derivatives as GABA A alpha 5 PAM | 豪夫迈·罗氏有限公司 | 2023-10-13 | — | — | CN | claimed |
| CN-115551841-A | Azetidin-3-ylcarbinol derivatives as modulators of the CCR6 receptor | 爱杜西亚药品有限公司 | 2022-12-30 | — | — | CN | claimed |
| EP-4021893-A1 | PERK INHIBITING COMPOUNDS | Hibercell, Inc. (US) | 2022-07-06 | — | — | EP | claimed |
| WO-2021041973-A1 | PERK INHIBITING COMPOUNDS | HIBERCELL, INC. (US) | 2021-03-04 | — | — | WO | claimed |
| EP-2649064-A1 | NOVEL TRIAZOLE COMPOUNDS III | F. Hoffmann-La Roche AG (CH) | 2013-10-16 | — | — | EP | claimed |
| WO-2012076590-A1 | NOVEL TRIAZOLE COMPOUNDS III | F. HOFFMANN-LA ROCHE AG (CH) | 2012-06-14 | — | — | WO | claimed |
| CN-117843567-A | Diazaaryl ring substituted benzene derivatives, compositions and uses thereof | 康迈迪森(北京)医药科技有限公司 | 2024-04-09 | — | — | CN | disclosed |
| CN-116478145-B | ALK2 kinase inhibitors | 杭州邦顺制药有限公司 | 2024-02-02 | — | — | CN | disclosed |
| CN-117285525-A | Novel isoxazolyl ether derivatives as GABAA alpha 5PAM | 豪夫迈·罗氏有限公司 | 2023-12-26 | — | — | CN | disclosed |
| WO-2023198114-A1 | ALK2 KINASE INHIBITOR | 杭州邦顺制药有限公司 | 2023-10-19 | — | — | WO | disclosed |
| CN-109923113-B | Isoxazolyl ether derivatives as GABA A alpha 5 PAM | 豪夫迈·罗氏有限公司 | 2023-10-13 | — | — | CN | disclosed |
| CN-116478145-A | ALK2 kinase inhibitors | 杭州邦顺制药有限公司 | 2023-07-25 | — | — | CN | disclosed |
| US-20230174514-A1 | AZETIDIN-3-YLMETHANOL DERIVATIVES AS CCR6 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2023-06-08 | — | — | US | disclosed |
| CN-107344936-B | Triazolopyridazine derivative, preparation method, pharmaceutical composition and application thereof | 上海赛默罗生物科技有限公司 | 2022-06-03 | — | — | CN | disclosed |
| EP-2575455-A2 | METHODS AND COMPOSITIONS FOR TREATING A SUBJECT FOR CENTRAL NERVOUS SYSTEM (CNS) INJURY | The Regents of the University of California (US) | 2013-04-10 | — | — | EP | disclosed |
| WO-2011153377-A2 | METHODS AND COMPOSITIONS FOR TREATING A SUBJECT FOR CENTRAL NERVOUS SYSTEM (CNS) INJURY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-12-08 | — | — | WO | disclosed |
| US-20080132505-A1 | Combination Of Cb2 Modulators And Pde4 Inhibitors For Use In Medicine | GLAXO GROUP LIMITED | 2008-06-05 | — | — | US | disclosed |
| EP-1565442-A1 | PYRIDINE DERIVATIVES AS CB2 RECEPTOR MODULATORS | GLAXO GROUP LIMITED (GB) | 2005-08-24 | — | — | EP | disclosed |
| WO-2004029026-A1 | PYRIDINE DERIVATIVES AS CB2 RECEPTOR MODULATORS | GLAXO GROUP LIMITED (GB) | 2004-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230174514-A1 | AZETIDIN-3-YLMETHANOL DERIVATIVES AS CCR6 RECEPTOR MODULATORS | CCR6, CCR1, CCR3 | ALDH1A1 1097/4885L3MBTL1 3610/4885HTT 3976/4885 |
| US-20080132505-A1 | Combination Of Cb2 Modulators And Pde4 Inhibitors For Use In Medicine | CNR2, CNR1, PDE4A | ALDH1A1 3032/4885L3MBTL1 4731/4885HTT 4329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.